AUROBINDO

February 29, 2016

Surveillance Department,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED,
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
MUMBAI - 400 051

Dear Sirs,

Sub: Clarification on News Item

Ref: 1) Your Letter No.NSE/CM/Surveillance/6183 dated February 29, 2016
2) Our Company Code No. AUROPHARMA

We refer to your letter dated 29.02.2016, with regard to the news item which appeared in the "Business Line" on "Aurobindo's anti HIV tablets". This is to clarify that the Company received Tentative approval for Ritonavir Tablet USP, 100mg from USFDA. Tentative approval is an interim approval when the product is under patent/exclusivities. The launch of an ANDA is subject to the Final approval and hence the tentative approval does not have any financial impact. Considering the same, as a process, the Company issue press release only after the Final approval.

This ANDA is approved out of Unit VII formulation facility in Hyderabad, India, used for manufacturing Oral Non-Antibiotic products.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

A.MOHAN RAMI REDDY
Vice President (Legal) & Company Secretary

AUROBINDO PHARMA LTD. ★ HYD. ★